Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-07-10

Clinical Trial Update: Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on safety, tolerability, and efficacy of Uproleselan (GMI-1271) in COVID-19 pneumonia, terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Uproleselan (GMI-1271) (uproleselan)

Snippet

Sponsor: Lena Napolitano, MD | Conditions: COVID-19 Pneumonia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-07-10